Stocks Health care PMVP
NASDAQ · Health carePMV Pharmaceuticals, Inc. (PMVP)
It posted a net loss of $75.2M. In fiscal 2025 capital spending exceeded operating cash flow by $73.6M. At June 30, 2026 it held $12.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about PMV Pharmaceuticals, Inc.
- Net worth
- PMV Pharmaceuticals, Inc. has a market value (market cap) of $65.8M at the latest share price, and shareholders' equity of $71.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $73.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- PMV Pharmaceuticals, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What PMV Pharmaceuticals, Inc. does
PMV Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker PMVP.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$77.7M | -$1.48 | -$73.6M |
| 2024 | n/a | -$58.7M | -$1.14 | -$51.9M |
| 2023 | n/a | -$69M | -$1.44 | -$56.6M |
| 2022 | n/a | -$73.3M | -$1.61 | -$71.7M |
| 2021 | n/a | -$57.8M | -$1.28 | -$47.9M |
| 2020 | n/a | -$34.4M | -$2.40 | -$32.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What PMV Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 5, 2026Executive or director change8-KPMV Pharmaceuticals appointed Dr. Matthew Eckler to its Board of Directors.
- September 15, 2026Passive stake (5% or more) SCHEDULE 13G
- September 2, 2026
- August 31, 2026Other event 8-K
- August 14, 2026
- August 14, 2026
- July 28, 2026Passive stake changed SCHEDULE 13G/A
- July 10, 2026Passive stake changed SCHEDULE 13G/A
- June 5, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
Insider trades
What the people running PMV Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns PMVP
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BML Investment Partners, L.P.13G, passive | 9.9% | February 9, 2026 |
| Srinivas Akkaraju13G, passive with 4 related filers | 9.9% | September 15, 2026 |
| Tang Capital Management, LLC13G, passive with 5 related filers | 8.9% | September 23, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 64 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BML Capital Management, LLC | 5,330,000 | +10,000 |
| Tang Capital Management LLC | 4,245,085 | 0 |
| Sio Capital Management, LLC | 2,634,137 | -442,443 |
| Euclidean Capital LLC | 2,627,643 | 0 |
| Adage Capital Partners GP, L.L.C. | 2,360,000 | +500,000 |
| Vanguard Capital Management LLC | 2,012,020 | +37,114 |
| ArrowMark Colorado Holdings LLC | 1,959,579 | -913,185 |
| Two Sigma Investments, LP | 1,954,136 | +69,606 |
| Eversept Partners, LP | 1,890,904 | -457,456 |
| BlackRock, Inc. | 919,818 | +45,444 |
| Assenagon Asset Management S.A. | 660,006 | +299,220 |
| Stonepine Capital Management, LLC | 536,086 | -172,016 |
| Geode Capital Management, LLC | 473,158 | -22,764 |
| Aldebaran Capital, LLC | 467,432 | -5,930 |
| Bridgeway Capital Management, LLC | 428,853 | 0 |
| BIT Capital GmbH | 407,555 | +284,000 |
| Verdad Advisers, LP | 362,361 | +182,200 |
| Walleye Capital LLC | 335,694 | 0 |
| Marshall Wace, Llp | 321,610 | -112,483 |
| Vanguard Fiduciary Trust Co | 254,775 | -43,351 |
Insiders
Questions about PMVP
What does PMV Pharmaceuticals, Inc. do?
PMV Pharmaceuticals, Inc. is a company in the Health care sector, listed on NASDAQ as PMVP. Its shares trade on NASDAQ under the ticker PMVP.
What is PMV Pharmaceuticals, Inc.'s net worth?
PMV Pharmaceuticals, Inc. has a market value (market cap) of $65.8M at the latest share price, and shareholders' equity of $71.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is PMV Pharmaceuticals, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $75.2M.
When did PMV Pharmaceuticals, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from October 5, 2026.
When is PMV Pharmaceuticals, Inc.'s next earnings report?
PMV Pharmaceuticals, Inc.'s next report is expected around November 11, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare PMVP with
Follow PMVP
Get an email when PMV Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values PMV Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.